

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 25 2002

Applicants: Michael Sworin and James C. Jenson

SEP 26 2002

Application No.: 10/082,815

Group Art Unit: 1645

TECH CENTER 1600/2900

Filed: February 22, 2002

Examiner: No Yet Assigned

Confirmation No.: 1636

Title: INHIBITORS OF BINDING BETWEEN PROTEINS AND MACROMOLECULAR LIGANDS

H8
Plunkett
10/22/02

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202

on 9/23/02 Sandra Brigham
Date Signature
SANDRA BRIGHAM
Typed or printed name of person signing certificate

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
P.O. Box 2327
Arlington, VA 22202

Sir:

This Information Disclosure Statement is submitted:

under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

under 37 CFR 1.97(c) together with either:

a Statement under 37 CFR 1.97(e), as checked below, or

a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with:

a Statement under 37 CFR 1.97(e), as checked below, and

a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

[X] Enclosed herewith is form PTO-1449:

- Copies of the cited references are enclosed.
- Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
 - the explanation provided on the attached sheet.
 - the explanation provided in the Specification.
 - submission of the enclosed International Search Report.
 - submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
 - the enclosed English language abstract.

RECEIVED

SEP 23 2002

TECH CENTER 1600/2000

Applicant requests that the following non-published pending applications be considered:

Examiner's Initials _____

U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner _____

Date _____

- A copy of each above-cited application, including the current claims, is enclosed.
- A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.


It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 

Steven G. Davis
Registration No.: 39,652
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:

September 23, 2002

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2791.1003-007	APPLICATION NO. 10/082,815 RECEIVED
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>September 20, 2002 SEP 25 2002</i> <i>(Use several sheets if necessary)</i>		APPLICANT Michael Sworin, et al.	SEP 26 2002
		FILING DATE February 22, 2002	GROUP 1645 <i>TECH CENTER 1600/2900</i>

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	5,474,911	12/12/95	Pontius			
	AB	5,612,034	3/18/97	Pouletty et al.	424	184.1	
	AC	5,698,401	12/16/97	Fesik et al.	435	7.1	
	AD	5,763,595	6/9/98	Gold et al.	536	2.1	
	AE	5,804,390	9/8/98	Fesik et al.	435	7.1	
	AF	5,843,440	12/1/98	Pouletty et al.	424	133.1	
	AG	5,891,643	4/6/99	Fesik et al.	435	7.1	
	AH	5,958,703	9/28/99	Dower et al.	435	7.1	
	AI	5,962,219	10/5/99	Gold et al.	435	6	
	AJ	5,989,827	11/23/99	Fesik et al.	435	7.1	
	AK	6,043,024	3/28/00	Fesik et al.	435	4	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	WO 97/25074	17-7-97	PCT			
	AM	WO 97/29372	14-8-97	PCT			
	AN	WO 98/11437	19-3-98	PCT			
	AO	WO 98/19162	7-5-98	PCT			
	AP	WO 98/46270	22-10-98	PCT			
	AQ	WO 98/47002	22-10-98	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	Way, J. C., "Covalent modification as a strategy to block protein-protein interactions with small-molecule drugs," <i>Current Opinion in Chemical Biology</i> , 4:40-46 (2000).
AS	Krantz, A., Diversification of the drug discovery process," <i>Nature Biotechnology</i> , Vol. 16:1294 (1998).
AT	Krantz, A., et al., "Drug Pharmacophores Covalently Linked to the Red Cell Surface are Active Without Prior Release. Drug Targeting of Renin with a Synthetic Ligand Conjugated to Red Blood Cells," <i>Journal of Drug Targeting</i> , 7(2):113-130 (1999).

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2791.1003-007	APPLICATION NO. 10/082,815
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		APPLICANT Michael Sworin et al.	SEP 25 2002
September 20, 2002 SEP 25 2002 (Use several sheets if necessary)		FILING DATE February 22, 2002	GROUP 1645 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA2	6,087,375	7/11/00	Bridon et al.	514	314	
	AB2	6,103,233	8/15/00	Pouletty et al.	424	133.1	
	AC2	6,107,489	8/22/00	Krantz et al.	548	338.1	
	AD2	5,705,337	1/6/98	Gold et al.	435	6	
	AE2						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL2	WO 99/24074	20-5-00	PCT			
	AM2	WO 99/24076	20-5-99	PCT			
	AN2	WO 99/24462	20-5-99	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AU	Krantz, A., "Red Cell-Mediated Therapy: Opportunities and Challenges," <i>Blood Cells, Molecules, and Diseases</i> , 23(3):58-68 (1997).
AV	Krantz, A., "Peptidyl (Acyloxy)methanes as Quiescent Affinity Labels for Cysteine Proteinases," <i>Methods in Enzymology</i> , 244:656-671 (1994).
AW	Weir, M. P., et al., "Novel Natural Product 5,5-trans-Lactone Inhibitors of Human α -Thrombin: Mechanism of Action and Structural Studies," <i>Biochemistry</i> , 37:6645-6657 (1998).
AX	Hemmerich, S., et al., "Identification of Residues in the Monocyte Chemotactic Protein-1 That Contact the MCP-1 Receptor, CCR2," <i>Biochemistry</i> , 38:13013-13025 (1999).
AY	Finch, H., et al., "5,5-TRANS LACTONE-CONTAINING INHIBITORS OF SERINE PROTEASES: IDENTIFICATION OF A NOVEL, ACYLATING THROMBIN INHIBITOR," <i>Bioorganic & Medicinal Chemistry Letters</i> , 8:2955-2960 (1998).
AZ	Monteclaro, F.S., et al., "The Amino-terminal Domain of CCR2 Is Both Necessary and Sufficient for High Affinity Binding of Monocyte Chemoattractant Protein 1," <i>The Journal of Biological Chemistry</i> , 272(37): 23186-23190 (1997).
AR2	Tilley, J.W., et al., "Identification of a Small Molecule Inhibitor of the IL-2/IL-2R α Receptor Interaction Which Binds to IL-2," <i>J. Am. Chem. Soc.</i> , 119:7589-7590 (1997).

EXAMINER	DATE CONSIDERED
----------	-----------------

RECEIVED

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
2791.1003-007APPLICATION NO.
10/082,815INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

September 20, 2002 SEP 25 2002

(Use several sheets if necessary)

APPLICANT
Michael Sworin et al.FILING DATE
February 22, 2002GROUP
1645

RECEIVED

SEP 20 002

TECH CENTER 1000/2

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AF2						
	AG2						
	AH2						
	AI2						
	AJ2						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AO2	WO 99/24075	20-6-99	PCT			
	AP2	WO 99/31265	24-6-99	PCT			
	AQ2	WO 99/48536	30-9-99	PCT			
	AL3	WO 99/64032	16-12-99	PCT			
	AM3	WO 99/64036	16-12-99	PCT			
	AN3	WO 99/66944	29-12-99	PCT			
	AO3	WO 00/00823	6-1-00	PCT			
	AP3	WO 00/39585	6-7-00	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AS2	Skelton, N. J., et al., "Structure of a CXC chemokine-receptor fragment in complex with interleukin-8," <i>Structure</i> 7(2):157-168 (1999).
AT2	Shuker, S.B., et al., "Discovering High-Affinity Ligands for Proteins: SAR by NMR," <i>Science</i> , 274:1531-1534 (1996).
AU2	Steitz, S.A., et al., "Mapping of MCP-1 functional domains by peptide analysis and site-directed mutagenesis," <i>FEBS Letters</i> , 430(158-164 (1998).
AV2	Reckless, J., et al., "Identification of oligopeptide sequences which inhibit migration induced by a wide range of chemokines," <i>Biochem. J.</i> , 340:803-811 (1999).
AW2	Spaldin, V., et al., "The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes," <i>Br J Clin Pharmac</i> , 38:15-22, (1994).

EXAMINER

DATE CONSIDERED